Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On July 15, 2020, Edwards Lifesciences Corporation, a Delaware corporation (the
"Company"), announced that Paul A. LaViolette was appointed to the Company's
Board of Directors, effective July 13, 2020. The Board also appointed
Mr. LaViolette to serve as a member of the Compensation and Governance Committee
of the Board of Directors.
There is no arrangement or understanding between Mr. LaViolette and any other
persons pursuant to which he was selected as a director. Mr. LaViolette has no
direct or indirect material interest in any transaction required to be disclosed
pursuant to Item 404(a) of Regulation S-K. Mr. LaViolette will receive the same
compensation for his services as a director as the Company's other nonemployee
directors as described under "Director Compensation" in the Company's 2020 Proxy
Statement filed with the Securities and Exchange Commission (the "SEC") on March
25, 2020. The Company will also enter into its standard form of indemnification
agreement with Mr. LaViolette, which agreement is filed as Exhibit 10.20 to the
Company's Form 10-K for the fiscal year ended December 31, 2011, filed with the
SEC on February 27, 2012.
A copy of the press release announcing his appointment is filed as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated July 15, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses